Aaron Stigers
Gerontology · Shreveport, LANPI 1114449071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,018 and has fallen 87.7% since, to $125 in 2025.
Across 102 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$381
- Merck$306
- AstraZeneca$250
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$245
- GSK$233
- Lilly USA, LLC$203
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $381 |
| Merck | 18 | $306 |
| AstraZeneca(2 entities) | 2 | $250 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $245 |
| GSK | 13 | $233 |
| Lilly USA, LLC | 6 | $203 |
| AbbVie | 1 | $125 |
| Genentech USA, Inc. | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Bayer | 5 | $106 |
| Novartis | 7 | $104 |
| Mylan Specialty L.p. | 5 | $95 |
| Pfizer | 4 | $72 |
| Sanofi | 1 | $53 |
| Novo Nordisk | 3 | $49 |
| Boehringer Ingelheim | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Evoke Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,725 in reported general payments places this provider in the 80th percentile of 64 gerontology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $28,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,283 |
| JanuviaSitagliptin Phosphate | 17 | $15,926 |
| EliquisApixaban | 11 | $8,862 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,658 |
| Pantoprazole Sodium | 83 | $827 |
| Gabapentin | 65 | $696 |
| Levothyroxine Sodium | 29 | $497 |
| Olmesartan Medoxomil | 22 | $452 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $425 |
| Atorvastatin Calcium | 39 | $402 |
| Sucralfate | 15 | $364 |
| Hydralazine Hcl | 14 | $356 |
| Potassium Chloride | 24 | $304 |
| Alprazolam | 91 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $43 | $28,96932 claims |
| GSKTrelegy Ellipta | $233 | $16,28317 claims |
| MerckJanuvia | $306 | $15,92617 claims |
| PfizerEliquis | $72 | $8,86211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 gerontology providers in Louisiana.
Other gerontology in Shreveport
- Elizabeth MangumShreveport$2K
- Jennifer StewartShreveport$2K
- Lisa TaylorShreveport$419
- Candice CrowShreveport$278
- Mary InmanShreveport$149
- Jodie HarrisonSlidell$12K
- Whitney StevensSlidell$10K
- Rebekah HendryBossier City$6K
- Jessica GaubertBaton Rouge$6K
- Kathy BernsteinNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.